Dihexa mastery course
Unit 1 of 10, free

What is dihexa?

An honest, evidence-first introduction to dihexa: what it is, where it came from, and why its foundational studies are under review.

Big animal claims, and human trials of its prodrug that failed

Dihexa (PNB-0408) is a small, fully synthetic molecule derived from angiotensin IV, invented by researchers at Washington State University and described by its developers as orally active and able to penetrate the blood-brain barrier. In rodents and cell culture it looks striking. No source this course cites reports it given to people as dihexa itself. The only human exposure those sources report is to the active form of an injected prodrug, fosgonimeton, which the body converts into dihexa, and every efficacy trial of that prodrug missed its primary endpoint.

This unit sets the honest picture first: what dihexa actually is, the discovery story, and why two of its foundational papers were later retracted or flagged. Everything here is education, not medical advice.

What you'll learn

What this course covers

10 units take you from the essentials to an in-depth understanding.

  1. 01 What is dihexa? Big animal claims, and human trials of its prodrug that failed free
  2. 02 Chemistry & structure How dihexa is built from angiotensin IV paid
  3. 03 The HGF/c-Met hypothesis The proposed mechanism, and why it is a hypothesis paid
  4. 04 The preclinical evidence What the animal and cell studies actually show paid
  5. 05 The research-integrity problem The retraction and the expression of concern paid
  6. 06 The fosgonimeton translation The prodrug that took dihexa into humans, and failed paid
  7. 07 Dosing & Administration What the community reports, and why no dose is established paid
  8. 08 Safety & Side Effects The c-Met oncology signal and the missing safety data paid
  9. 09 Regulatory context Not approved, and in regulatory limbo paid
  10. 10 Final Exam & Certification Pass the final exam to earn your certificate of completion. Exam

Key terms

Where dihexa came from

Dihexa was not discovered by accident. Researchers at Washington State University invented it, out of the Harding and Wright group's long-running work on how a fragment of the blood-pressure hormone system, angiotensin IV, could sharpen memory in rodents. Along the way the group used a more stable version of angiotensin IV, then trimmed it to a short core before modifying that core into dihexa.

The research timeline

Notice how the marketing-friendly story arrived late and then partly collapsed. The clean, early work is about angiotensin IV analogs and spines; the bold HGF/c-Met headline came in 2014 and was retracted in 2025.

AdvancedWhy the lineage matters

Dihexa is best understood as the last, most drug-like member of an angiotensin IV analog series, not as a novel invention. Reading it that way keeps the cognitive claims tethered to the older, more careful rodent work rather than to the flashier growth-factor story layered on later.

What the molecule actually is

Dihexa is often called a "hexapeptide". Chemically it is not: it is a core of just two building blocks (two residues, tyrosine and isoleucine) wearing two fatty caps. The 2013 paper that named it, which is under a notice of concern, describes those chemical modifications as designed to increase hydrophobicity, meaning how strongly the molecule avoids water and favors fat, and to decrease hydrogen bonding, yielding an orally active, blood-barrier permeant, metabolically stabilized analog.

The core residues

The chemical name does the describing that the short name does not: N-hexanoic-Tyr-Ile-(6)aminohexanoic amide is a hexanoyl group, a two-residue core, and a 6-aminohexanoyl amide. No source in this course's research explains where the short name "dihexa" comes from, so treat it as a nickname and read the chemical name instead. That is where most misunderstandings of dihexa begin, so it is worth fixing early.

AdvancedThe full chemical name, unpacked

The formal name is N-hexanoic-Tyr-Ile-(6)aminohexanoic amide. Read left to right: a hexanoyl cap, the tyrosine-isoleucine core, then a 6-aminohexanoyl amide cap. The FDA's substance registry gives its molecular formula as C27H44N4O5 and its molecular weight as 504.6631, and lists PNB-0408 and ATH-1001 among its other names. ATH-1001 is also the name the human trial paper on its prodrug, fosgonimeton, uses for the active compound.

The claims you will meet online

Search dihexa and you will meet confident superlatives: "reverses Alzheimer's", "regrows neurons", "ten million times stronger than BDNF". Each is either an overreach, a result borrowed from a different molecule, or a number no cited study supports at all. The useful skill is holding each claim against its actual evidence.

Popular claims, checked
The claims in numbers

Most of these claims are not simply false. They are real laboratory observations that have been rounded up into human promises they cannot support, or numbers whose origin nobody checks. Learning to see that gap is what this course trains.

The honest evidence ceiling

Before any mechanism detail, here is the honest ceiling: what is genuinely supported for dihexa, and what is merely hoped for. The distance between the top and bottom rows of this table is the entire point of the course. Read down the tiers and notice how quickly the evidence thins, from a real but narrow animal signal at the top to human trials of an injected prodrug that missed their primary endpoints at the bottom.

How strong is the flagship claim?

A gauge this low is unusual for a compound with so much online enthusiasm, and that mismatch is the story. The score is not a verdict that dihexa does nothing; it is a measure of how little we can actually claim to know about it in people.

Important

This course is education, not medical advice, and nothing here is a recommendation to use dihexa or any dose of it.

Potency is not efficacy

The "ten million times stronger than BDNF" line deserves a careful look. Taken at face value it is a potency statement, about how low a concentration produces an effect in a dish, not about how well either molecule treats a human brain. It is worth separating those two questions before worrying about the number, because no paper this course cites reports it.

Two different questions

A drug can be extraordinarily potent and still completely fail, because potency is a laboratory concentration and efficacy is a clinical result. Conflating the two is an easy error to make when reading any potency claim, dihexa's included.

AdvancedWhere the number traces back to

Not to any study of dihexa this course cites. The figure appears in its sources only secondhand: the FDA's substance record for dihexa quotes a Wikipedia sentence saying that in an assay of neurotrophic activity dihexa was seven orders of magnitude, ten million times, more potent than BDNF, and names no study. The nearest published comparison is for the parent compound, not dihexa: the 2011 paper used BDNF as a positive control in its spine assay and reports that the BDNF concentration needed for equivalent increases in dendritic spines was seven orders of magnitude greater than the Nle1-angiotensin IV concentration. That is a potency comparison for a different peptide. A 2021 rat nerve-repair paper says neurotrophic activity seven times greater, credited to an earlier publication, with no BDNF measured in that study, and the 2013 paper that named dihexa gives no BDNF comparison for dihexa. The 2011 abstract also reports a correlation between a peptide's procognitive activity and its capacity to increase spine numbers and enlarge spine head size, for Nle1-angiotensin IV analogs rather than for dihexa. Treat an untraceable statistic the way you would treat an unsigned quote: not as false, but as something nobody has shown you the source for.

What this course covers

The rest of the course walks the evidence in order: the chemistry, the proposed mechanism, the preclinical data, the integrity actions, the failed prodrug trials, the dosing and safety picture, and the regulatory limbo. Each unit keeps the same honest posture.

The road ahead

By the end you should be able to state cleanly what is established, what is hypothesized, and what is simply unknown about dihexa, and to spot the claims that blur those lines.

AdvancedHow to read the evidence tags

Throughout, widgets are color-coded by evidence tier: solid, moderate, weak, and missing. When you see a claim, look for the tier before the wording. A confident sentence sitting on a weak or missing tier is exactly the pattern to distrust.


Knowledge check


Practice